TNF and juvenile idiopathic arthritis: Currently, there are five biologic agents targeting TNFα that are approved for treating various conditions such as rheumatoid arthritis, juvenile idiopathic arthritis (JIA), psoriatic arthritis, inflammatory bowel disease and ankylosing spondylitis.